3 June 2019 - Agency will work closely with physicians seeking treatments through its “expanded access” program. ...
4 June 2019 - U.S. FDA grants priority review for beta-thalassemia indication and sets target action date of 4 December ...
4 June 2019 - The U.S. FDA has accepted the new drug application for the investigational fixed-dose combination tablet of empagliflozin, ...
3 June 2019 - Current regulations prohibit the US FDA from publicly disclosing the existence of pending new drug applications or ...
3 June 2019 - The FDA sets new goal date of 6 October 2019 to complete review and issue risk-benefit decision. ...
3 June 2019 - SpringWorks Therapeutics today announced that the U.S. FDA has granted fast track designation for PD-0325901, an investigational, ...
3 June 2019 - The U.S. FDA today approved a new indication for the previously FDA approved drug, Zerbaxa (ceftolozane and ...
3 June 2019 - Today, the U.S. FDA Oncology Center of Excellence announced a new pilot program to assist oncology health ...
29 May 2019 - Officials with the FDA have given priority review designation to an opioid-free pain management treatment from ...
3 June 2019 - The U.S. FDA recently granted capmatinib breakthrough therapy designation for the treatment of patients with metastatic NSCLC ...
31 May 2019 - A family in Iowa believes the FDA will decide whether their only surviving daughter lives or ...
30 May 2019 - 26 September 2019 PDUFA date. ...
30 May 2019 - Submission follows productive pre-NDA meeting and marks on-time execution of first of two NDA submissions planned for ...
30 May 2019 - Phase 3 ADMIRAL trial showed patients treated with Xospate demonstrated longer overall survival than those who ...
29 May 2019 - I.V. Triferic was developed through Special Protocol Assessment with FDA based on equivalence approach to Dialysate Triferic. ...